2022
Oxygen Supplementation and Hyperoxia in Critically Ill Cardiac Patients From Pathophysiology to Clinical Practice
Thomas A, van Diepen S, Beekman R, Sinha SS, Brusca SB, Alviar CL, Jentzer J, Bohula EA, Katz JN, Shahu A, Barnett C, Morrow DA, Gilmore EJ, Solomon MA, Miller PE. Oxygen Supplementation and Hyperoxia in Critically Ill Cardiac Patients From Pathophysiology to Clinical Practice. JACC Advances 2022, 1: 100065. PMID: 36238193, PMCID: PMC9555075, DOI: 10.1016/j.jacadv.2022.100065.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsOxygen supplementationIntensive care unit cliniciansHarmful hemodynamic effectsAdverse clinical outcomesIll cardiac patientsManagement of patientsAcute cardiac diseaseAcute myocardial infarctionDirect cellular toxicityCoronary vasoconstrictionPulmonary hypertensionRespiratory failureHemodynamic effectsHeart failureOxygen therapyClinical outcomesSupplemental oxygenAvailable trialsCardiac arrestMyocardial infarctionCardiac patientsCardiac diseaseClinical practiceCardiovascular systemHyperoxia
2016
Availability of Clinical Trial Data From Industry‐Sponsored Cardiovascular Trials
Murugiah K, Ritchie JD, Desai NR, Ross JS, Krumholz HM. Availability of Clinical Trial Data From Industry‐Sponsored Cardiovascular Trials. Journal Of The American Heart Association 2016, 5: e003307. PMID: 27098969, PMCID: PMC4859296, DOI: 10.1161/jaha.116.003307.Peer-Reviewed Original ResearchConceptsIndividual participant-level dataLarge cardiovascular trialsCardiovascular trialsParticipant-level dataClinical trial dataPharmaceutical companiesMajor pharmaceutical companiesIndustry-sponsored clinical trialsInterventional trialsAvailable trialsClinical trialsTrial dataTrialsPatientsSpecific reasons
2008
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
Lin NU, Winer EP. Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. Journal Of Clinical Oncology 2008, 26: 798-805. PMID: 18258989, DOI: 10.1200/jco.2007.15.0946.Peer-Reviewed Original ResearchConceptsPostmenopausal womenAromatase inhibitorsEndocrine therapyBreast cancerHormone receptor-positive breast cancerHormone receptor-positive cancersInitial breast cancer diagnosisReceptor-positive breast cancerMost postmenopausal womenUpfront aromatase inhibitorsYears of tamoxifenAdjuvant endocrine therapyDisease-free survivalReceptor-positive cancersCommon tumor subtypeBreast cancer diagnosisPostmenopausal settingEndocrine treatmentOverall survivalDisease recurrenceRandomized trialsAvailable trialsIndividual patientsHigh riskTumor subtypes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply